The Hidden Risk of GLP-1 Medications: Osteopenia and How to Protect Your Bone Health Anneliese Cadena, A-GNP-C, MSN, RN Feb 5, 2025 3 min read GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) have revolutionized weight management and diabetes care, offering significant benefits in blood sugar control, appetite suppression, and weight loss
Phase 3 trials are currently underway and expected to conclude by 2025-2026 Regulatory review processes add 12-18 months after trial completion UK availability is realistically expected around 2026-2027 at earliest NHS access would require NICE approval following MHRA licensing Private prescription availability may precede NHS access Preparing for Future Treatment Options While waiting for Retatrutide to become available, there are meaningful steps you can take to prepare for future weight management treatments and improve your health in the meantime
Every batch is HPLC-verified by an independent laboratory
The best choices are usually plain, soft, and portioned modestly
